Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-08-17

Johnson & Johnson (JNJ)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$32,758,111
Joaquin Duato total, FY2025
77th
CEO pay percentile vs peers
360:1
CEO-to-median pay ratio
94.7%
Say-on-pay support, latest vote
Companies that benchmark against JNJ
37 companies name JNJ as a compensation peer

Each company listed discloses JNJ in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named JNJ in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Joaquin Duato$1,600,000$0$15,028,948$5,927,995$4,298,700$5,301,237$601,231$32,758,111
Chairman/CEO
Joseph Wolk1,240,64606,263,4862,470,5031,860,5602,455,025115,22214,405,442
EVP, CFO
Jennifer Taubert1,220,30806,160,6652,430,0132,002,7502,126,36489,96314,030,063
EVP, WWC Innovative Medicine
John Reed1,220,30806,160,6652,430,0131,810,000458,000135,07612,214,062
EVP, Innovative Medicine, R&D
Tim Schmid942,30803,422,4731,349,9981,507,8002,026,12788,0599,336,765
EVP, WWC, MedTech

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Joaquin Duato$32,758,111$24,302,360$28,397,240+8,455,751
Joseph Wolk14,405,44212,617,56813,914,853+1,787,874
Jennifer Taubert14,030,06311,190,04510,995,394+2,840,018
John Reed12,214,0629,304,43020,647,350+2,909,632
Tim Schmid9,336,76511,862,938−2,526,173

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Dividend-equivalent accruals2026-04-2312,02711 insiders, 11 accrual rows
John ReedEVP, Innovative Medicine, R&D2026-05-01A25,25500CommonForm 4 ↗
John ReedEVP, Innovative Medicine, R&D2026-05-01D11,0022302,528,810CommonForm 4 ↗
John ReedEVP, Innovative Medicine, R&D2026-05-01D25,25500Derivative, Class A CommonForm 4 ↗
Marillyn A. HewsonDirector2026-06-09A214.7923350,000Derivative, Class A CommonForm 4 ↗
Daniel E. PintoDirector2026-06-09A134.2423331,250Derivative, Class A CommonForm 4 ↗
Eugene A. WoodsDirector2026-06-09A161.0923337,500Derivative, Class A CommonForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11A10,0001161,156,700CommonForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11D10,0002412,411,500Common, open-market saleForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11D10,00000Derivative, Class A CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D23,0542515,792,686Common, open-market saleForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20A11,1291301,441,317CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D11,92500Derivative, Class A CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D11,12900Derivative, Class A CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20A11,9251321,573,385CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 25 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Eugene A. WoodsDirector2026-04-23A975$0$0Derivative, Class A CommonForm 4 ↗
Daniel E. PintoDirector2026-04-23A1,71200Derivative, Class A CommonForm 4 ↗
Hubert JolyDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Mary C. BeckerleDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Marillyn A. HewsonDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Nadja Y. WestDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
John G. MorikisDirector2026-04-23A1,54000Derivative, Class A CommonForm 4 ↗
Mark B. McClellanDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Paula A. JohnsonDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Mark A. WeinbergerDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
Jennifer A. DoudnaDirector2026-04-23A97500Derivative, Class A CommonForm 4 ↗
John ReedEVP, Innovative Medicine, R&D2026-05-01A25,25500CommonForm 4 ↗
John ReedEVP, Innovative Medicine, R&D2026-05-01D11,0022302,528,810CommonForm 4 ↗
John ReedEVP, Innovative Medicine, R&D2026-05-01D25,25500Derivative, Class A CommonForm 4 ↗
Marillyn A. HewsonDirector2026-06-09A214.7923350,000Derivative, Class A CommonForm 4 ↗
Daniel E. PintoDirector2026-06-09A134.2423331,250Derivative, Class A CommonForm 4 ↗
Eugene A. WoodsDirector2026-06-09A161.0923337,500Derivative, Class A CommonForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11A10,0001161,156,700CommonForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11D10,0002412,411,500Common, open-market saleForm 4 ↗
Kathryn E. WengelEVP, Chief TO and Risk Officer2026-06-11D10,00000Derivative, Class A CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D23,0542515,792,686Common, open-market saleForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20A11,1291301,441,317CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D11,92500Derivative, Class A CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20D11,12900Derivative, Class A CommonForm 4 ↗
Vanessa BroadhurstEVP, Global Corp Affairs2026-07-20A11,9251321,573,385CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Tim SchmidPSU2025-02-1519,090$2,972,523
Joaquin DuatoPSU2025-02-1583,82813,052,942
Jennifer TaubertRSU2025-02-155,539809,968
John ReedPSU2025-02-1534,3635,350,697
Tim SchmidOPTION2025-02-1549,8781,349,998
Jennifer TaubertPSU2025-02-1534,3635,350,697
John ReedRSU2025-02-155,539809,968
Joseph WolkRSU2025-02-155,632823,567
Joaquin DuatoOPTION2025-02-15219,0205,927,995
John ReedOPTION2025-02-1589,7812,430,013
Jennifer TaubertOPTION2025-02-1589,7812,430,013
Joaquin DuatoRSU2025-02-1513,5131,976,006
Joseph WolkOPTION2025-02-1591,2772,470,503
Joseph WolkPSU2025-02-1534,9365,439,919
Tim SchmidRSU2025-02-153,077449,950
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Tim Schmid$449,950$2,972,523$1,349,99862.3%
Joaquin Duato1,976,00613,052,9425,927,99562.3%
Jennifer Taubert809,9685,350,6972,430,01362.3%
John Reed809,9685,350,6972,430,01362.3%
Joseph Wolk823,5675,439,9192,470,50362.3%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Joaquin DuatoOption133,516151.41
Joaquin DuatoOption110,868131.94
Jennifer TaubertOption91,324151.41
Joaquin DuatoOption118,544157.92
Joseph WolkOption91,277156.15
Jennifer TaubertOption89,781156.15
Jennifer TaubertOption82,127164.62
Jennifer TaubertOption43,391129.51
Tim SchmidOption22,527151.41
John ReedOption43,442157.92
Tim SchmidOption17,431165.89
Tim SchmidOption8,998129.51
Tim SchmidOption4,129162.75
Joaquin DuatoRSU131,65227,334,905
Joaquin DuatoOption219,020156.15
Joaquin DuatoOption123,291115.67
Jennifer TaubertRSU53,96811,205,376
Joaquin DuatoRSU83,90617,421,403
Joaquin DuatoOption105,307129.51
Joaquin DuatoRSU73,05315,167,994
Jennifer TaubertOption43,712115.67
Joaquin DuatoOption114,776164.62
Joseph WolkRSU54,86711,392,035
John ReedRSU53,96811,205,376
Joseph WolkRSU44,9209,326,740
Joseph WolkOption88,219151.41
Jennifer TaubertOption67,397131.94
Joaquin DuatoOption99,811165.89
Joseph WolkOption79,280165.89
John ReedOption89,781156.15
Joseph WolkOption66,386131.94
Joseph WolkOption63,464157.92
Joseph WolkOption80,976164.62
Jennifer TaubertOption80,055165.89
John ReedRSU30,7496,384,415
Joseph WolkRSU37,4637,778,443
Jennifer TaubertRSU36,3257,542,160
Tim SchmidRSU29,9816,224,955
Joaquin DuatoOption57,416162.75
Tim SchmidOption49,878156.15
Jennifer TaubertRSU27,4125,691,554
Jennifer TaubertOption51,320157.92
John ReedRSU25,2555,243,696
Tim SchmidRSU23,4324,865,186
Tim SchmidOption33,105157.92
Joseph WolkOption29,444162.75
Joseph WolkOption19,241115.67
Joaquin DuatoRSU13,5132,805,704
Jennifer TaubertOption21,544162.75
Tim SchmidOption15,571101.87
Tim SchmidOption21,574164.62
Tim SchmidOption13,625115.67
Joaquin DuatoRSU7,3641,528,987
Joseph WolkOption12,066129.51
Tim SchmidOption11,070131.94
Joseph WolkRSU5,6321,169,372
Jennifer TaubertRSU5,5391,150,063
John ReedRSU5,5391,150,063
Tim SchmidRSU4,378909,004
Joseph WolkRSU3,942818,477
Joaquin DuatoRSU3,469720,268
Jennifer TaubertRSU3,188661,924
Tim SchmidRSU3,077638,878
John ReedRSU2,698560,186
Tim SchmidRSU2,056426,887
Tim SchmidRSU499103,607
Joseph WolkRSU1,779369,374
Jennifer TaubertRSU1,302270,334
05

Incentive-plan design — the Compensation Discussion & Analysis

The Company's compensation program is designed to attract, retain, and motivate leaders, aligning pay with performance and shareholder value.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultantSemler Brossy Consulting Group
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-04-231,641,173,03291,774,9239,607,17494.7%Passed
20252025-04-241,559,332,581142,483,9007,360,00991.63%Passed
20242024-04-251,511,199,544159,356,3739,366,86690.46%Passed
20232023-04-271,685,320,654123,275,64711,076,73093.18%Passed
20222022-04-281,579,815,895257,738,12811,483,56885.97%Passed
20212021-04-22986,844,148753,486,15290,895,69356.7%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-04-2394.7%a
20252025-04-2491.63%b
20242024-04-2590.46%c

a. Approved under the standard stated in the filing — “For purposes of determining the number of votes cast with respect to these matters, only those cast "For" or "Against" are included; abstentions and broker non-votes are counted only for purposes of determining whether a quorum is present at the Annual Meeting.”.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)360 : 1
CEO total compensation$32,784,511
Median employee compensation$91,000
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Marillyn A. HewsonIndependent · Lead Independent Director · Compensation & Benefits · Nominating & Corporate Governance (Chair) · Special Committee - Orthopaedics Separation (Chair)$200,000$205,000$8,000$413,000
Mary C. BeckerleIndependent · Regulatory Compliance & Sustainability · Science & Technology (Chair)150,000205,00020,000375,000
Jennifer A. DoudnaIndependent · Nominating & Corporate Governance · Science & Technology125,000205,00040,000370,000
Hubert JolyIndependent · Audit (Chair) · Nominating & Corporate Governance · Special Committee - Orthopaedics Separation142,548205,00020,000367,548
Mark A. WeinbergerIndependent · Audit · Regulatory Compliance & Sustainability (Chair) · Special Committee - Orthopaedics Separation150,000205,0000355,000
Nadja Y. WestIndependent · Regulatory Compliance & Sustainability · Science & Technology · Special Committee - Orthopaedics Separation125,000205,00020,000350,000
Eugene A. WoodsIndependent · Compensation & Benefits (Chair) · Regulatory Compliance & Sustainability142,158205,0000347,158
Paula A. JohnsonIndependent · Nominating & Corporate Governance · Science & Technology125,000205,00014,000344,000
Mark B. McClellanIndependent · Regulatory Compliance & Sustainability · Science & Technology125,000205,0000330,000
Darius AdamczykIndependent · Audit (Chair) · Departed during FY64,6540064,654
Daniel E. PintoIndependent · Audit · Compensation & Benefits · Special Committee - Orthopaedics Separation · Partial-year service · Newly elected62,5000062,500
John G. MorikisIndependent · Audit · Compensation & Benefits · Partial-year service · Newly elected39,127020,00059,127
Anne M. MulcahyIndependent · Nominating/Governance (Chair) · Departed during FY46,9520046,952
Joaquin DuatoEmployee director · Board Chair · Finance0
09

Board fee structure and ownership guideline

Annual cash retainer$125,000
Annual equity retainer$220,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)30,000 / 25,000 / 25,000
Stock ownership guideline5x annual cash retainer
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$1,497,939
Equity awards (grant-date value)$1,845,000
All other compensation$142,000
Total cost of the board$3,484,939

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Johnson & Johnson names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Johnson & Johnson.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Microsoft Corporation (MSFT)(9)2025Satya Nadella$2,500,000$84,245,496$0$9,555,000$96,496,790
2Intel Corporation2025Lip-Bu Tan746,20049,639,50039,523,2002,374,00092,990,900
3Eli Lilly and Company2025David Ricks1,700,00023,325,00006,485,50036,698,337
4Johnson & Johnson2025Joaquin Duato1,600,00015,028,9485,927,9954,298,70032,758,111
5Abbvie Inc.2025Robert Michael1,700,00013,268,4563,199,1545,200,00032,530,984
6AT T Inc.2025John Stankey2,400,00019,500,01206,272,00029,906,872
7Pfizer Inc.2025Albert Bourla1,800,0009,442,7058,998,1415,400,00027,585,301
8RTX Corporation2025Christopher Calio1,525,00010,875,3916,753,909024,846,826
9Amgen Inc.2025Robert Bradway1,925,40912,599,5895,399,9963,907,00024,693,120
10Abbott Laboratories2025Robert Ford1,500,0008,787,3788,788,4301,968,75024,198,660
11The Boeing Company2025Robert Ortberg1,500,0007,874,8189,624,9593,930,00023,581,389
12Medtronic plc2026Geoffrey Martha1,399,03913,672,2005,175,5592,307,20022,940,252
13Bristol Myers Squibb Company2025Christopher Boerner1,586,34616,061,39903,754,68421,879,919
14Merck Co., Inc.2025Robert Davis1,645,30212,102,8383,380,0042,326,50020,797,845

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Johnson & Johnsonnot disclosednot disclosednot disclosedSemler Brossy Consulting Group
Abbott Laboratories75.0%Options 50 · PSU 50NoMeridian Compensation Partners, LLC
Abbvie Inc.not disclosedPSU 40 · RSU 40 · Options 20Yes — Relative TSRSemler Brossy
Amgen Inc.136.0%PSU 50 · Options 30 · RSU 20Yes — relative TSRFrederic W. Cook & Co., Inc. (FW Cook)
AT T Inc.112%PSU 75 · RSU 25Yes — Relative Total Stockholder Return (TSR) Payout ModifierFrederic W. Cook & Co., Inc. (FW Cook)
Bristol Myers Squibb Company157.66%PSU 60 · MSU 40Yes — 3-Year Relative TSR CAGRFarient Advisors LLC
Eli Lilly and Company218%PSU 100NoFW Cook
Intel Corporation118.7%PSU 60 · Options 40Yes — TSR relative to S&P 500 IndexSemler Brossy
Medtronic plc103%PSU 50 · Options 30 · RSU 20NoSemler Brossy
Merck Co., Inc.94%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (R-TSR)FW Cook
Microsoft Corporation (MSFT)(9)not disclosedPSA 100not disclosedPay Governance LLC
Pfizer Inc.150%PSU 50 · MSU 50Yes — relative TSR as compared to the NYSE Arca Pharmaceutical Index (DRG Index or DRG)Meridian Compensation Partners, LLC
RTX Corporation164%PSU 60 · Options 40Yes — TSR vs. Core A&D PeersFW Cook
The Boeing Company131%Options 55 · RSU 45not disclosedFW Cook (Frederic W. Cook & Co., Inc.)

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

FAQ

Frequently asked questions

Who was the highest-paid executive at Johnson & Johnson in fiscal 2025?
As disclosed, the highest-paid executive at Johnson & Johnson in fiscal 2025 was Joaquin Duato, Chairman/CEO, with total compensation of $32,758,111.
How does Johnson & Johnson's chief executive pay compare to its disclosed peer group?
The filing shows that Joaquin Duato's pay placed him in the 77th percentile of the disclosed peer group.
What is Johnson & Johnson's CEO-to-median employee pay ratio?
As disclosed, the CEO-to-median employee pay ratio was 360:1.
How did shareholders vote on Johnson & Johnson's executive compensation?
The filing shows that 94.7% of shareholders supported the latest executive compensation vote.
How much does Johnson & Johnson spend in total on board compensation for fiscal 2025?
As disclosed, total board compensation for fiscal 2025 was $3,484,939.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Joaquin DuatoDEF 14A2026-03-110000200406-26-000063Section “summary compensation table”. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246
2Section 01, Joseph WolkDEF 14A2026-03-110000200406-26-000063Section “summary compensation table”. As printed: 14,405,442. Filing ↗machine: r6 · c27 · span 1630843–1630853
3Section 01, Jennifer TaubertDEF 14A2026-03-110000200406-26-000063Section “summary compensation table”. As printed: 14,030,063. Filing ↗machine: r9 · c27 · span 1640403–1640413
4Section 01, John ReedDEF 14A2026-03-110000200406-26-000063Section “summary compensation table”. As printed: 12,214,062. Filing ↗machine: r12 · c27 · span 1649964–1649974
5Section 01, Tim SchmidDEF 14A2026-03-110000200406-26-000063Section “summary compensation table”. As printed: 9,336,765. Filing ↗machine: r15 · c27 · span 1659503–1659512
6Section 03, Tim Schmid PSUDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t212 · r8 · c11 · span 1684650–1684659
7Section 03, Joaquin Duato PSUDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t212 · r4 · c11 · span 1673623–1673633
8Section 03, Jennifer Taubert RSUDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
9Section 03, John Reed PSUDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t212 · r7 · c11 · span 1681603–1681612
10Section 03, Tim Schmid OPTIONDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t275 · r7 · c6 · span 2542542–2542551
11Section 03, Jennifer Taubert PSUDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t212 · r6 · c11 · span 1678942–1678951
12Section 03, John Reed RSUDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
13Section 03, Joseph Wolk RSUDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
14Section 03, Joaquin Duato OPTIONDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t275 · r3 · c6 · span 2531818–2531827
15Section 03, John Reed OPTIONDEF 14A2026-03-110000200406-26-000063Section “EVP, WWC I” · grants of plan-based awards table. Filing ↗machine: t210 · r12 · c8 · span 1648580–1648589
16Section 03, Jennifer Taubert OPTIONDEF 14A2026-03-110000200406-26-000063Section “EVP, WWC I” · grants of plan-based awards table. Filing ↗machine: t210 · r9 · c8 · span 1639018–1639027
17Section 03, Joaquin Duato RSUDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
18Section 03, Joseph Wolk OPTIONDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t275 · r4 · c6 · span 2534525–2534534
19Section 03, Joseph Wolk PSUDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t212 · r5 · c11 · span 1676278–1676287
20Section 03, Tim Schmid RSUDEF 14A2026-03-110000200406-26-000063Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗
21Section 07, pay ratioDEF 14A2026-03-110000200406-26-000063Section “CEO Pay Ratio”. As printed: 360 : 1. Filing ↗machine: span 2348958–2348966
22Section 08, Marillyn A. HewsonDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 413,000. Filing ↗
23Section 08, Mary C. BeckerleDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 375,000. Filing ↗
24Section 08, Jennifer A. DoudnaDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 370,000. Filing ↗
25Section 08, Hubert JolyDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 367,548. Filing ↗
26Section 08, Mark A. WeinbergerDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 355,000. Filing ↗
27Section 08, Nadja Y. WestDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 350,000. Filing ↗
28Section 08, Eugene A. WoodsDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 347,158. Filing ↗
29Section 08, Paula A. JohnsonDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 344,000. Filing ↗
30Section 08, Mark B. McClellanDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 330,000. Filing ↗
31Section 08, Darius AdamczykDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 64,654. Filing ↗
32Section 08, Daniel E. PintoDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 62,500. Filing ↗
33Section 08, John G. MorikisDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 59,127. Filing ↗
34Section 08, Anne M. MulcahyDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 46,952. Filing ↗machine: span 940580–940586
35Section 08, Joaquin DuatoDEF 14A2026-03-110000200406-26-000063Section “Director Compensation”. As printed: 0. Filing ↗
36Section 02, Eugene A. Woods 2026-04-23Form 42026-04-270000200406-26-000113Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Daniel E. Pinto 2026-04-23Form 42026-04-270000200406-26-000106Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Hubert Joly 2026-04-23Form 42026-04-270000200406-26-000100Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Mary C. Beckerle 2026-04-23Form 42026-04-270000200406-26-000092Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Marillyn A. Hewson 2026-04-23Form 42026-04-270000200406-26-000096Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Nadja Y. West 2026-04-23Form 42026-04-270000200406-26-000111Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, John G. Morikis 2026-04-23Form 42026-04-270000200406-26-000104Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Mark B. McClellan 2026-04-23Form 42026-04-270000200406-26-000102Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Paula A. Johnson 2026-04-23Form 42026-04-270000200406-26-000098Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Mark A. Weinberger 2026-04-23Form 42026-04-270000200406-26-000108Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Jennifer A. Doudna 2026-04-23Form 42026-04-270000200406-26-000094Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, John Reed 2026-05-01Form 42026-05-040000200406-26-000115Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, John Reed 2026-05-01Form 42026-05-040000200406-26-000115Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, John Reed 2026-05-01Form 42026-05-040000200406-26-000115Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Marillyn A. Hewson 2026-06-09Form 42026-06-110000200406-26-000121Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Daniel E. Pinto 2026-06-09Form 42026-06-110000200406-26-000123Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Eugene A. Woods 2026-06-09Form 42026-06-110000200406-26-000125Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Kathryn E. Wengel 2026-06-11Form 42026-06-120000200406-26-000127Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Kathryn E. Wengel 2026-06-11Form 42026-06-120000200406-26-000127Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Kathryn E. Wengel 2026-06-11Form 42026-06-120000200406-26-000127Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Vanessa Broadhurst 2026-07-20Form 42026-07-210000200406-26-000148Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Vanessa Broadhurst 2026-07-20Form 42026-07-210000200406-26-000148Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Vanessa Broadhurst 2026-07-20Form 42026-07-210000200406-26-000148Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Vanessa Broadhurst 2026-07-20Form 42026-07-210000200406-26-000148Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Vanessa Broadhurst 2026-07-20Form 42026-07-210000200406-26-000148Insider equity transaction reported since the proxy statement. Filing ↗
61Section 06, 2026 voteForm 8-K2026-04-280000200406-26-000089Item 5.07 · say-on-pay result. As reported: 94.7% (votes for as printed: 1,641,173,032). Filing ↗
62Section 06, 2025 voteForm 8-K2025-04-300000200406-25-000141Item 5.07 · say-on-pay result. As reported: 91.63% (votes for as printed: 1,559,332,581). Filing ↗
63Section 06, 2024 voteForm 8-K2024-04-290000200406-24-000043Item 5.07 · say-on-pay result. As reported: 90.46% (votes for as printed: 1,511,199,544.00). Filing ↗
64Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
65Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
66Section 09b board cost (computed)ComputedcomputedCash 1,497,939 + equity 1,845,000 + all other 142,000 = 3,484,939, summed across the director compensation table rows.machine: formula: Σ = 3,484,939
67Microsoft Corporation (MSFT)(9), Section 10b CEO totalDEF 14A2025-10-210001193125-25-245150CEO total compensation as printed in Microsoft Corporation (MSFT)(9)'s own proxy. As printed: 96,496,790. Filing ↗machine: r2 · c27 · span 1059364–1059374
68Intel Corporation, Section 10b CEO totalDEF 14A2026-03-230000050863-26-000061CEO total compensation as printed in Intel Corporation's own proxy. As printed: 92,990,900. Filing ↗machine: r2 · c24 · span 1612980–1612990
69Eli Lilly and Company, Section 10b CEO totalDEF 14A2026-03-200000059478-26-000029CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. Filing ↗machine: t92 · r2 · c20 · span 925013–925024
70Johnson & Johnson (subject), Section 10b CEO totalDEF 14A2026-03-110000200406-26-000063CEO total compensation as printed in Johnson & Johnson's own proxy. As printed: 32,758,111. Filing ↗machine: r3 · c27 · span 1621235–1621246
71Abbvie Inc., Section 10b CEO totalDEF 14A2026-03-230001104659-26-033387CEO total compensation as printed in Abbvie Inc.'s own proxy. As printed: 32,530,984. Filing ↗machine: t210 · r9 · c26 · span 1414083–1414093
72AT T Inc., Section 10b CEO totalDEF 14A2026-03-230001193125-26-119888CEO total compensation as printed in AT T Inc.'s own proxy. As printed: 29,906,872. Filing ↗machine: t295 · r3 · c35 · span 1189292–1189302
73Pfizer Inc., Section 10b CEO totalDEF 14A2026-03-120000078003-26-000033CEO total compensation as printed in Pfizer Inc.'s own proxy. As printed: 27,585,301. Filing ↗machine: t242 · r3 · c12 · span 1506825–1506835
74RTX Corporation, Section 10b CEO totalDEF 14A2026-03-090001308179-26-000036CEO total compensation as printed in RTX Corporation's own proxy. As printed: 24,846,826. Filing ↗machine: t237 · r2 · c14 · span 908955–908966
75Amgen Inc., Section 10b CEO totalDEF 14A2026-04-070001193125-26-145588CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. Filing ↗machine: span 1591156–1591166
76Abbott Laboratories, Section 10b CEO totalDEF 14A2026-03-130001308179-26-000064CEO total compensation as printed in Abbott Laboratories's own proxy. As printed: 24,198,660. Filing ↗machine: span 1245488–1245498
77The Boeing Company, Section 10b CEO totalDEF 14A2026-03-060001193125-26-096787CEO total compensation as printed in The Boeing Company's own proxy. As printed: 23,581,389. Filing ↗machine: r2 · c44 · span 1170571–1170581
78Medtronic plc, Section 10b CEO totalDEF 14A2026-08-170001613103-26-000010CEO total compensation as printed in Medtronic plc's own proxy. As printed: 22,940,252. Filing ↗machine: span 988220–988230
79Bristol Myers Squibb Company, Section 10b CEO totalDEF 14A2026-03-250000014272-26-000006CEO total compensation as printed in Bristol Myers Squibb Company's own proxy. As printed: 21,879,919. Filing ↗machine: t168 · r3 · c15 · span 1302160–1302170
80Merck Co., Inc., Section 10b CEO totalDEF 14A2026-04-080001193125-26-147704CEO total compensation as printed in Merck Co., Inc.'s own proxy. As printed: 20,797,845. Filing ↗machine: span 1371012–1371022
81Section 10a, Abbvie Inc. reciprocityDEF 14A0001104659-26-033387Abbvie Inc. names Johnson & Johnson in its own disclosed peer group (read from its most recent proxy). Filing ↗
82Section 10a, AT T Inc. reciprocityDEF 14A0001193125-26-119888AT T Inc.'s most recent proxy was read; its disclosed peer group does not include Johnson & Johnson. Filing ↗
83Section 10a, Pfizer Inc. reciprocityDEF 14A0000078003-26-000033Pfizer Inc. names Johnson & Johnson in its own disclosed peer group (read from its most recent proxy). Filing ↗
84Section 10a, Amgen Inc. reciprocityDEF 14A0001193125-26-145588Amgen Inc. names Johnson & Johnson in its own disclosed peer group (read from its most recent proxy). Filing ↗
85Section 10a, Intel Corporation reciprocityDEF 14A0000050863-26-000061Intel Corporation's most recent proxy was read; its disclosed peer group does not include Johnson & Johnson. Filing ↗
86Section 10a, The Boeing Company reciprocityDEF 14A0001193125-26-096787The Boeing Company names Johnson & Johnson in its own disclosed peer group (read from its most recent proxy). Filing ↗
87Section 10a, Eli Lilly and Company reciprocityDEF 14A0000059478-26-000029Eli Lilly and Company names Johnson & Johnson in its own disclosed peer group (read from its most recent proxy). Filing ↗
88Section 10a, Bristol Myers Squibb Company reciprocityDEF 14A0000014272-26-000006Bristol Myers Squibb Company names Johnson & Johnson in its own disclosed peer group (read from its most recent proxy). Filing ↗
89Section 10a, Microsoft Corporation (MSFT)(9) reciprocityDEF 14A0001193125-25-245150Microsoft Corporation (MSFT)(9) names Johnson & Johnson in its own disclosed peer group (read from its most recent proxy). Filing ↗
90Section 10a, RTX Corporation reciprocityDEF 14A0001308179-26-000036RTX Corporation's most recent proxy was read; its disclosed peer group does not include Johnson & Johnson. Filing ↗
91Section 10a, Merck Co., Inc. reciprocityDEF 14A0001193125-26-147704Merck Co., Inc. names Johnson & Johnson in its own disclosed peer group (read from its most recent proxy). Filing ↗